| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
COO & Cbo | Chief Operating & Bo | Chief Operating Officer
1 company
Joshua Hexter is COO & Cbo at ORMP. Joshua Hexter's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $5.5M at current prices.
The ORMP filings lean toward selling, a net 167,000 shares.
Joshua Hexter has 20 Form 4 filings on record from November 2016 to October 2026, all as COO & Cbo at Oramed Pharmaceuticals (ORMP), 2016–2026.
The 30 reported transactions were 17 stock awards, 6 option or other derivative awards, 3 dispositions back to the company and 2 open-market sales, plus smaller numbers of other types.
Counted by filing, the open-market trades come to no purchases and 2 sales worth about $747K.
The largest open-market sale was 137,000 shares of ORMP at an average $4.46 on July 1, 2026, about $611K.
1 of the 2 sales since April 2023 was made under a Rule 10b5-1 trading plan; the other was not.